Skip to content

Assessment of therapeutic success after interstitial brachytherapy of hepatocellular carcinoma using the LI-RADS-TRA algorithm

Assessment of therapeutic success after interstitial brachytherapy of hepatocellular carcinoma using the LI-RADS-TRA algorithm - LI-RADS TRA- LMU-RAD01160

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00033714
Enrollment
20
Registered
2024-05-29
Start date
2024-06-21
Completion date
Unknown
Last updated
2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C22.0

Interventions

Group 1: The hospital's electronic database will be searched for all patients who received interstitial brachytherapy and subsequent transplantation. Clinical and laboratory data are collected for eac

Sponsors

LMU München
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: • HCC patients =18 years • Z.n. Primary brachytherapy for HCC at the LMU Clinic with subsequent liver transplant • Presence of multiphasic MRI up to a maximum of 90 days before brachytherapy • At least one multiphase MRI scan after brachytherapy up to a maximum of 90 days before transplantation • No additional treatment of HCC before transplantation

Exclusion criteria

Exclusion criteria: • Incomplete imaging or insufficient imaging that interferes with correct image interpretation (e.g. due to artifacts).

Design outcomes

Primary

MeasureTime frame
Correlation LR-TRA with histopathology.

Secondary

MeasureTime frame
Interreader Agreement LR-TRA pre- and post-interventional, diagnostic performance of MRI for predicting histological tumor necrosis

Countries

Germany

Contacts

Public ContactOsman Oecal

LMU München

Osman.Oecal@med.uni-muenchen.de+4989440076642

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026